Investment Rating - The report maintains a "Buy" recommendation for 康哲药业 (0867.HK) with a current stock price of 13.59 HKD [1][3]. Core Insights - 康哲药业's revenue for 2025 reached 82.12 billion CNY, representing a year-on-year growth of 9.9%. The normalized annual profit was 17.76 billion CNY, showing a growth of 3.6% after excluding a one-time tax payment of 2.79 billion CNY [4][7]. - The company is experiencing a harvest period for its innovative products, with sales from core innovative and exclusive drugs reaching 56.13 billion CNY, a growth of 23.3% [7][8]. - The company is accelerating its innovation and research, with two new drugs approved for market release in early 2026, contributing to its growth strategy [7][8]. Financial Summary - Revenue projections for 康哲药业 are as follows: 98.33 billion CNY in 2026, 116.45 billion CNY in 2027, and 139.43 billion CNY in 2028, with growth rates of 19.7%, 18.4%, and 19.7% respectively [6][8]. - Net profit estimates are projected at 19.79 billion CNY for 2026, 22.80 billion CNY for 2027, and 27.16 billion CNY for 2028, with growth rates of 32.9%, 15.2%, and 19.1% respectively [6][8]. - The gross margin is expected to stabilize around 72.5% in 2026, with a net margin of 19.8% [6][8].

Summary of 康哲药业 Conference Call Company Overview - 康哲药业 is undergoing a strategic transformation from original research drugs to innovative drugs, driven by both collaborative development and independent research. The company has received approval for 5 innovative drugs covering 6 indications and is actively expanding internationally, including a secondary listing in Singapore without involving financing or equity dilution [2][4]. Key Business Segments - The company operates four main business segments: - Cardiovascular and Digestive Health: Stabilized after the impact of the National Volume-Based Procurement (VBP) - Ophthalmology: Strong profitability - Skin Health: 德美医药 is set for a spin-off listing - International Business: Focused on Southeast Asia, expected to contribute to future growth [2][5]. Financial Performance - The core products' revenue has declined due to VBP, with projected revenue of 2.6 billion yuan for three core products in 2024. However, the impact of centralized procurement is expected to be cleared, leading to a phase of rapid growth as innovative drugs are approved [2][7]. - The company’s key product portfolio includes: - Existing national procurement products (波依定, 黛力新, 优思弗) expected to contribute 2.6 billion yuan in 2024 - Exclusive and brand drugs anticipated to maintain around 10% growth [8]. Innovative Product Pipeline - 康哲药业 has nearly 20 self-researched projects, with 5-6 in clinical development. Key upcoming products include: - Y3 injection for stroke treatment, expected to exceed 3 billion yuan in sales - ABP671 for hyperuricemia, with NDA submission expected in mid-2025 - 德西度司他片 for chronic kidney disease anemia, expected to be approved this year [3][10][12][13]. Impact of VBP - The company faced significant impacts from VBP, with core products previously accounting for over 50% of sales. The sales retention rate post-VBP was around 50% [6][7]. Spin-off of 德美医药 - The spin-off of 德美医药 is expected to be completed by the end of 2025, which will not significantly affect 康哲药业's overall financial status but will help improve its valuation. 康哲 will distribute 90.8% of 德美 shares to shareholders [3][15]. Market Expansion and Internationalization - 康哲药业 is expanding into Southeast Asia, establishing a regional headquarters in Singapore and planning a secondary listing. This move aims to explore new growth avenues without limiting business development [20][21]. R&D and Sales Expenses - In 2025, 康哲's R&D and sales expenses are expected to rise due to high costs associated with marketing and brand building for newly launched innovative drugs. Profit growth is anticipated to lag behind revenue growth this year, but significant profit increases are expected starting in 2026 as 德美 is no longer consolidated [22][23]. Conclusion - 康哲药业 is positioned for growth through its innovative drug pipeline and international expansion, despite facing challenges from VBP. The upcoming spin-off of 德美医药 and the focus on Southeast Asian markets are strategic moves to enhance overall company valuation and market presence.